Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.71−0.21 (-1.92%)
Close on Nov 17, 2026Market cap $654.78MP/E –Yield –
Janux Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Janux Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$41.25M. For fiscal 2025 it was -$82.24M. The highest annual figure on record is -$4.37M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$82.24M | – |
| FY2024 | Dec 31, 2024 | -$43.81M | – |
| FY2023 | Dec 31, 2023 | -$50.58M | – |
| FY2022 | Dec 31, 2022 | -$42.92M | – |
| FY2021 | Dec 31, 2021 | -$16.98M | – |
| FY2020 | Dec 31, 2020 | -$4.37M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.48M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$28.54M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.81M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.02M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.84M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.90M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.71M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.05M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.91M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$6.07M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.52M | -307.1% |
| Q4 FY2021 | Dec 31, 2021 | -$10.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.85M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.20M | – |
| Q1 FY2021 | Mar 31, 2021 | $5.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.63M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.08M | – |
See a number that looks wrong?